“We live in a system that favors high-profit medicines. Those are the only things in play, and they don’t work. They are failing,” says Dr. Pierre Kory, a pulmonary and critical care specialist. He’s the president of the Frontline COVID-19 Critical Care Alliance. Two years into this pandemic, why haven’t there been more clinical trials of repurposed drugs to treat COVID-19? “It’s not about ivermectin. It’s about the pharmaceutical industry capture of our agencies, and at suppressing and avoiding the use of cheap, repurposed drugs," says Kory.